| " Evidence for overuse of medical services around the world": Erratum. S Brownlee, K Chalkidou, J Doust, AG Elshaug, P Glasziou, I Heath, ... Lancet, 2022 | 2 | 2022 |
| “What should happen before asymptomatic men decide whether or not to have a PSA test?” A report on three community juries C Degeling, L Rychetnik, K Pickles, R Thomas, JA Doust, RA Gardiner, ... Medical Journal of Australia 203 (8), 335-335, 2015 | 14 | 2015 |
| 023 Chat-GP: partnering with consumers, clinicians & stakeholders to codesign shared decision making resources for heart health checks C Bonner, J Doust, M Morgan, K Greaves, CDE Wet, D O’Connor, ... BMJ Evidence-Based Medicine 29 (Suppl 1), A11-A11, 2024 | | 2024 |
| 049 Women’s interest, knowledge, and a> tudes towards an@-mullerian hormone tes@ ng: a randomised trial T Copp, T van Nieuwenhoven, K McCaffery, K Hammarberg, J Doust, ... BMJ Evidence-Based Medicine 29 (Suppl 1), A21-A22, 2024 | | 2024 |
| 1 in 6 women are diagnosed with gestational diabetes. But this diagnosis may not benefit them or their babies PP Glasziou, J Doust The Conversation, 2023 | | 2023 |
| 11 Reporting lab results: the cause of, and the solution to, the overdiagnosis problem J McCormack, J Doust, C Bell BMJ Evidence-Based Medicine 23 (Suppl 2), A5-A5, 2018 | | 2018 |
| 118 Communicating cardiovascular disease risk with women who have a history of pregnancy complications and loss B Jenkinson, S Lawler, P Middleton, C Bonner, E Cooke, L Hardiman, ... BMJ Evidence-Based Medicine 29 (Suppl 1), A53-A53, 2024 | | 2024 |
| 1252Agreement between self-reported chlamydia infection and chlamydia infection ascertained using testing and medication administrative data. L Wilson, A Dobson, J Doust, G Mishra International Journal of Epidemiology 50, 2021 | | 2021 |
| 127 Community awareness and use of anti-Mullerian hormone (AMH) testing in Australia: A population survey of women aged 18–55 years T Copp, R Thompson, K Hammarberg, J Doust, S Lensen, M Peate, ... BMJ Evidence-Based Medicine 27 (Suppl 1), A28-A29, 2022 | | 2022 |
| 2 What’s in a name? Defining and labelling disease and its role in reducing overdiagnosis and overtreatment K McCaffery, S Carter, R Thomas, C Degeling, B Nickel, T Copp, ... BMJ Evidence-Based Medicine 24 (Suppl 2), A1-A1, 2019 | 1 | 2019 |
| 23 Heart age: intuitive communication tool or gateway to overdiagnosis? A comparison of 3 countries C Bonner, S McKinn, K McCaffery, P Glasziou, J Doust, J Jansen, K Bell BMJ Evidence-Based Medicine 24 (Suppl 2), A18-A18, 2019 | | 2019 |
| 41 Will the use of high sensitivity troponin result in overdiagnosis of myocardial infarction? J Doust, P Glasziou BMJ Evidence-Based Medicine 23 (Suppl 2), A18-A18, 2018 | | 2018 |
| 49 Applying the checklist for modifying the definition of disease to attention deficit/hyperactivity disorder (ADHD) age of onset criterion (AOC) R Thomas, S Sanders, P Glasziou, J Doust BMJ Evidence-Based Medicine 23 (Suppl 2), A22-A22, 2018 | | 2018 |
| 54 A mapping review of empirical research on defensive practice N Ries, C Hacker, K McCaffery, A Elsaug, J Doust, J Jansen BMJ Evidence-Based Medicine 24 (Suppl 2), A32-A32, 2019 | | 2019 |
| 75 Kidney trajectory charts to guide management of reduced kidney function in general practice: a randomised controlled scenario study M Guppy, P Glasziou, J Doust, E Beller, R Flavel BMJ Evidence-Based Medicine 24 (Suppl 2), A42-A43, 2019 | | 2019 |
| 76 Widening disease definitions in gestational diabetes: an evaluation of changing guidelines C Naaktgeboren, J Doust, P Glasziou, J Lowe, M Leeflang BMJ Evidence-Based Medicine 23 (Suppl 2), A35-A35, 2018 | | 2018 |
| 8 Clinical practice guidelines were adapted and implemented meeting country-specific requirementsdthe example of Kazakhstan Jessie McGowan, Sergei Muratov, Anna Tsepke, Arman … G Gartlehner, A Dobrescu, TS Evans, K Thaler, B Nussbaumer, I Sommer, ... | | |
| 86 Medico-legal experts’ views on psychosocial drivers of defensive practice: a qualitative interview study N Ries, C Hacker, K McCaffery, A Elsaug, J Doust, J Jansen BMJ Evidence-Based Medicine 24 (Suppl 2), A48-A49, 2019 | | 2019 |
| 89 Incremental benefits and harms of the 2017 american college of cardiology/american heart association high blood pressure guideline K Bell, J Doust, P Glasziou BMJ Evidence-Based Medicine 23 (Suppl 2), A42-A42, 2018 | | 2018 |
| 94 Under-versus overdiagnosis: exploring the benefits and harms of a PCOS label and its impact on women’s psychosocial wellbeing, lifestyle and behaviour T Copp, J Hersch, K McCaffery, J Doust, A Dokras, B Mol, J Jansen BMJ Evidence-Based Medicine 23 (Suppl 2), A44-A44, 2018 | | 2018 |
